Capricor reviewing operations after FDA rejects cell therapy
FROM THE WIRE · SEEKINGALPHA.COM
Capricor Therapeutics (CAPR) stock falls as the FDA declines to approve cell therapy candidate Deramiocel. Read more here.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe FDA rejection of a key candidate weighs on the shares of this small biotech.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA declined to approve the cell therapy candidate Deramiocel.
- 02Capricor Therapeutics shares are falling.
- 03The company is reviewing its operations.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets